Sign up to access all valuation multiples
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focuses on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
1998
9.6K+
LTM Revenue $889M
LTM EBITDA $210M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Asymchem Laboratories has a last 12-month revenue (LTM) of $889M and a last 12-month EBITDA of $210M.
In the most recent fiscal year, Asymchem Laboratories achieved revenue of $808M and an EBITDA of $221M.
Asymchem Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Asymchem Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $889M | XXX | $808M | XXX | XXX | XXX |
| Gross Profit | $383M | XXX | $342M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $210M | XXX | $221M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $155M | XXX | $97.8M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $152M | XXX | $132M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Asymchem Laboratories's stock price is CNY 105 (or $15).
Asymchem Laboratories has current market cap of CNY 37.9B (or $5.3B), and EV of CNY 30.8B (or $4.3B).
See Asymchem Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $5.3B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Asymchem Laboratories has market cap of $5.3B and EV of $4.3B.
Asymchem Laboratories's trades at 5.3x EV/Revenue multiple, and 19.4x EV/EBITDA.
Equity research analysts estimate Asymchem Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Asymchem Laboratories has a P/E ratio of 34.6x.
See valuation multiples for Asymchem Laboratories and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 20.4x | XXX | 19.4x | XXX | XXX | XXX |
| EV/EBIT | 27.7x | XXX | 43.8x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.6x | XXX | 40.0x | XXX | XXX | XXX |
| EV/FCF | 69.6x | XXX | 247.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAsymchem Laboratories's last 12 month revenue growth is 15%
Asymchem Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $25K for the same period.
Asymchem Laboratories's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Asymchem Laboratories's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Asymchem Laboratories and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | -26% | XXX | XXX | XXX |
| Rule of 40 | 54% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Asymchem Laboratories acquired XXX companies to date.
Last acquisition by Asymchem Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Asymchem Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Asymchem Laboratories founded? | Asymchem Laboratories was founded in 1998. |
| Where is Asymchem Laboratories headquartered? | Asymchem Laboratories is headquartered in China. |
| How many employees does Asymchem Laboratories have? | As of today, Asymchem Laboratories has 9.6K+ employees. |
| Who is the CEO of Asymchem Laboratories? | Asymchem Laboratories's CEO is Dr. Hao Hong. |
| Is Asymchem Laboratories publicy listed? | Yes, Asymchem Laboratories is a public company listed on SHE. |
| What is the stock symbol of Asymchem Laboratories? | Asymchem Laboratories trades under 002821 ticker. |
| When did Asymchem Laboratories go public? | Asymchem Laboratories went public in 2016. |
| Who are competitors of Asymchem Laboratories? | Similar companies to Asymchem Laboratories include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Asymchem Laboratories? | Asymchem Laboratories's current market cap is $5.3B |
| What is the current revenue of Asymchem Laboratories? | Asymchem Laboratories's last 12 months revenue is $889M. |
| What is the current revenue growth of Asymchem Laboratories? | Asymchem Laboratories revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Asymchem Laboratories? | Current revenue multiple of Asymchem Laboratories is 4.8x. |
| Is Asymchem Laboratories profitable? | Yes, Asymchem Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Asymchem Laboratories? | Asymchem Laboratories's last 12 months EBITDA is $210M. |
| What is Asymchem Laboratories's EBITDA margin? | Asymchem Laboratories's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Asymchem Laboratories? | Current EBITDA multiple of Asymchem Laboratories is 20.4x. |
| What is the current FCF of Asymchem Laboratories? | Asymchem Laboratories's last 12 months FCF is $61.6M. |
| What is Asymchem Laboratories's FCF margin? | Asymchem Laboratories's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Asymchem Laboratories? | Current FCF multiple of Asymchem Laboratories is 69.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
